Evidence map›Paper›PMID 30262735›Full record

ReviewMolecules (Basel, Switzerland)2018

Cannabinoid Delivery Systems for Pain and Inflammation Treatment.

Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi, Franco Dosio

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06695195 (A Randomized Controlled Trial of Oral CBD for the Treatment of Upper Extremity Musculoskeletal Pain), which is not on this map. Cited by 114 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06695195 phase1not yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized Controlled Trial of Oral CBD for the Treatment of Upper Extremity Musculoskeletal Pain

TypeinterventionalSponsorBrent DeGeorgeRan2025 to 2026Enrolled100ConditionsUpper Extremity Muscle Pain, Upper Extremity Bone Pain, Upper Extremity PainArmsCannabidiol (CBD), Placebo
3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Natascia BruniIstituto Farmaceutico Candioli, 10092 Beinasco, Italy. natascia.bruni@candioli.it.ORCID 0000-0003-4062-8006
Carlo Della PepaDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy. carlo.dellapepa@unito.it.
Simonetta Oliaro-BossoDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy. simona.oliaro@unito.it.
Enrica PessioneDepartment of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy. enrica.pessione@unito.it.
Daniela GastaldiDepartment of Molecular Biotechnology and Health Sciences, University of Turin, 10125 Turin, Italy. daniela.gastaldi@unito.it.
Franco DosioDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy. franco.dosio@unito.it.ORCID 0000-0003-1128-9922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and safety. The low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration and transmucosal adsorption, being proposed. The highly lipophilic nature of cannabinoids means that they are seen as suitable candidates for advanced nanosized drug delivery systems, which can be applied via a range of routes. Nanotechnology-based drug delivery strategies have flourished in several therapeutic fields in recent years and numerous drugs have reached the market. This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment. Likely future directions are also considered and reported.

Indexed as

CannabinoidsNanotechnologyAnimalsClinical Trials as TopicDrug Delivery SystemsHumansInflammationPainCannabinoidscannabidiolcannabinoidsdelivery systeminflammationpain treatmentΔ9-tetrahydrocannabinol

Identifiers

PMID30262735
PMCPMC6222489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.